Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
268 Treffer:
21.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-03
22.
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-03
23.
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-03
24.
Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment.
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-03
25.
A Multicentre, Randomized Trial in Adults With de Novo Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia to Assess the Efficacy of Ponatinib Versus Imatinib in Combination With Low-intensity Chemotherapy, to Compare End of Therapy With Indicat
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute lymphatische Leukämie
Datum: 2026-04-03
26.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute lymphatische Leukämie
Datum: 2026-04-03
27.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Ovarialkarzinom
Datum: 2026-04-03
28.
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FR?-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Ovarialkarzinom
Datum: 2026-04-03
29.
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Ovarialkarzinom
Datum: 2026-04-03
30.
Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Ovarialkarzinom
Datum: 2026-04-03